Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1999 Apr;64(4):963–970. doi: 10.1086/302320

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

P Hartge 1, J P Struewing 1, S Wacholder 1, L C Brody 1, M A Tucker 1
PMCID: PMC1377820  PMID: 10090881

Abstract

Three founder mutations in the cancer-associated genes BRCA1 and BRCA2 occur frequently enough among Ashkenazi Jews to warrant consideration of genetic testing outside the setting of high-risk families with multiple cases of breast or ovarian cancer. We estimated the prevalence of these founder mutations in BRCA1 and BRCA2 in the general population of Ashkenazi Jews according to age at testing, personal cancer history, and family cancer history. We compared the results of anonymous genetic testing of blood samples obtained in a survey of >5,000 Jewish participants from the Washington, DC, area with personal and family cancer histories obtained from questionnaires completed by the participants. In all subgroups defined by age and cancer history, fewer mutations were found in this community sample than in clinical series studied to date. For example, 11 (10%) of 109 Jewish women who had been given a diagnosis of breast cancer in their forties carried one of the mutations. The most important predictor of mutation status was a previous diagnosis of breast or ovarian cancer. In men and in women never given a diagnosis of cancer, family history of breast cancer before age 50 years was the strongest predictor. As interest in genetic testing for BRCA1 and BRCA2 in the Jewish community broadens, community-based estimates such as these help guide those seeking and those offering such testing. Even with accurate estimates of the likelihood of carrying a mutation and the likelihood of developing cancer if a mutation is detected, the most vexing clinical problems remain.

Full Text

The Full Text of this article is available as a PDF (206.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beller U., Halle D., Catane R., Kaufman B., Hornreich G., Levy-Lahad E. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol. 1997 Nov;67(2):123–126. doi: 10.1006/gyno.1997.4844. [DOI] [PubMed] [Google Scholar]
  2. Berry D. A., Parmigiani G., Sanchez J., Schildkraut J., Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 5;89(3):227–238. doi: 10.1093/jnci/89.3.227. [DOI] [PubMed] [Google Scholar]
  3. Couch F. J., DeShano M. L., Blackwood M. A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B. L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997 May 15;336(20):1409–1415. doi: 10.1056/NEJM199705153362002. [DOI] [PubMed] [Google Scholar]
  4. Fodor F. H., Weston A., Bleiweiss I. J., McCurdy L. D., Walsh M. M., Tartter P. I., Brower S. T., Eng C. M. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998 Jul;63(1):45–51. doi: 10.1086/301903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frank T. S., Manley S. A., Olopade O. I., Cummings S., Garber J. E., Bernhardt B., Antman K., Russo D., Wood M. E., Mullineau L. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul;16(7):2417–2425. doi: 10.1200/JCO.1998.16.7.2417. [DOI] [PubMed] [Google Scholar]
  6. Gayther S. A., Mangion J., Russell P., Seal S., Barfoot R., Ponder B. A., Stratton M. R., Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997 Jan;15(1):103–105. doi: 10.1038/ng0197-103. [DOI] [PubMed] [Google Scholar]
  7. Lee J. S., Wacholder S., Struewing J. P., McAdams M., Pee D., Brody L. C., Tucker M. A., Hartge P. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999 Feb 3;91(3):259–263. doi: 10.1093/jnci/91.3.259. [DOI] [PubMed] [Google Scholar]
  8. Lerman C., Narod S., Schulman K., Hughes C., Gomez-Caminero A., Bonney G., Gold K., Trock B., Main D., Lynch J. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 1996 Jun 26;275(24):1885–1892. [PubMed] [Google Scholar]
  9. Levy-Lahad E., Catane R., Eisenberg S., Kaufman B., Hornreich G., Lishinsky E., Shohat M., Weber B. L., Beller U., Lahad A. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  10. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  11. Modan B., Gak E., Sade-Bruchim R. B., Hirsh-Yechezkel G., Theodor L., Lubin F., Ben-Baruch G., Beller U., Fishman A., Dgani R. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA. 1996 Dec 11;276(22):1823–1825. [PubMed] [Google Scholar]
  12. Oddoux C., Struewing J. P., Clayton C. M., Neuhausen S., Brody L. C., Kaback M., Haas B., Norton L., Borgen P., Jhanwar S. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996 Oct;14(2):188–190. doi: 10.1038/ng1096-188. [DOI] [PubMed] [Google Scholar]
  13. Offit K., Gilewski T., McGuire P., Schluger A., Hampel H., Brown K., Swensen J., Neuhausen S., Skolnick M., Norton L. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996 Jun 15;347(9016):1643–1645. doi: 10.1016/s0140-6736(96)91484-1. [DOI] [PubMed] [Google Scholar]
  14. Richards C. S., Ward P. A., Roa B. B., Friedman L. C., Boyd A. A., Kuenzli G., Dunn J. K., Plon S. E. Screening for 185delAG in the Ashkenazim. Am J Hum Genet. 1997 May;60(5):1085–1098. [PMC free article] [PubMed] [Google Scholar]
  15. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., Pruss D., Tavtigian S. V., Teng D. H., Adey N. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997 Oct 15;278(15):1242–1250. [PubMed] [Google Scholar]
  16. Struewing J. P., Abeliovich D., Peretz T., Avishai N., Kaback M. M., Collins F. S., Brody L. C. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995 Oct;11(2):198–200. doi: 10.1038/ng1095-198. [DOI] [PubMed] [Google Scholar]
  17. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  18. Thorlacius S., Struewing J. P., Hartge P., Olafsdottir G. H., Sigvaldason H., Tryggvadottir L., Wacholder S., Tulinius H., Eyfjörd J. E. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998 Oct 24;352(9137):1337–1339. doi: 10.1016/s0140-6736(98)03300-5. [DOI] [PubMed] [Google Scholar]
  19. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986 Jan;123(1):174–184. doi: 10.1093/oxfordjournals.aje.a114212. [DOI] [PubMed] [Google Scholar]
  20. Wacholder S., Hartge P., Struewing J. P., Pee D., McAdams M., Brody L., Tucker M. The kin-cohort study for estimating penetrance. Am J Epidemiol. 1998 Oct 1;148(7):623–630. doi: 10.1093/aje/148.7.623. [DOI] [PubMed] [Google Scholar]
  21. Whittemore A. S., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997 Mar;60(3):496–504. [PMC free article] [PubMed] [Google Scholar]
  22. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES